Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis.

Kyle S McCommisWesley T HodgesElizabeth M BruntIlke NalbantogluWilliam G McDonaldChristopher L HolleyHideji FujiwaraJean E SchafferJerry R ColcaBrian N Finck

Published in: Hepatology (Baltimore, Md.) (2017)

Collectively, these data demonstrate the effectiveness of MSDC-0602 for attenuating NASH in a rodent model and suggest that targeting hepatic MPC2 may be an effective strategy for pharmacologic development. (Hepatology 2017;65:1543-1556).

Keyphrases

mouse model
cancer therapy
randomized controlled trial
systematic review
oxidative stress
big data
deep learning
artificial intelligence